Healthcare Biz Review: J&J’s NEW TB Drug, Arena GIVES BACK Again

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Amarin (NASDAQ:AMRN) nears receiving a long-sought patent for its top drug candidate, AMR101, after the USPTO issues a Notice of Allowance supporting the use of the fish-oil heart med in patients with high triglycerides. Such a notice is typically issued following a decision by regulators that a patent can be granted from an application. An FDA ruling on AMR101 is expected in July.

Don’t Miss: The Week Ahead on Wall Street: Short Holiday Week, BLS Unemployment.

Johnson & Johnson (NYSE:JNJ) is requesting an accelerated FDA approval for bedaquiline, which is the first new type of medication for the treatment of tuberculosis in more than four decades, and is the first for specifically fighting the increasingly common strain of TB that is resistant to multiple drugs. The filing is supported by data from the firm’s Phase II trial.

Arena Pharmaceuticals (NASDAQ:ARNA) gave back more (but not all) of the gigantic gains it saw following FDA approval of its weight-loss drug Belviq. However, Vivus (NASDAQ:VVUS) shares are still advancing ahead of an FDA decision on the firm’s Qnexa diet drug scheduled for July 17.

Don’t Miss: Here are the STUDS and DUDS of the DOW for 2012.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business